Incyclix Bio Is Betting One Precise Brake Can Stop Cancer's Second Escape Route

A 13-person North Carolina biotech licensed an overlooked CDK2 program, narrowed the patient target and pushed one oral drug into the clinic. Early data offer a reason to keep going - and a useful blueprint for building around a precise scientific thesis rather than a sprawling pipeline.